Skip to main content
SpringerLink
Log in

Toxidermies avec manifestations systémiques

  • Chapter
Book cover Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées

  • 544 Accesses

Abstrait

Les toxidermies sont définies comme les complications cutanéo-muqueuses secondaires à l’administration par voie entérale, intraveineuse, sous-cutanée ou intramusculaire de médicaments. Elles constituent l’une des complications iatrogéniques les plus courantes en termes de morbidité et de mortalité. Elles affectent 2 à 3% des patients hospitalises1. Les plus fréquentes sont l’exanthème maculo-papuleux et ’urticaire dont les évolutions sont presque toujours favorables. À lľopposé, les formes graves de toxidermie et susceptibles de mettre en jeu le pronostic vital sont rares (2 à 5%)1, 2. Elles sont représentées par l’anaphylaxie, les vasculites médicamenteuses, la pustulose exanthématique aiguë généralisée, le syndrome DRESS/syndrome d’hypersensibilité médicamenteuse et la nécrolyse épidermique toxique (syndromes de Stevens-Johnson et de Lyell).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wolf R, Orion E, Marcos B, Matz H. Lifethreatening acute adverse cutaneous drug reactions. Clin Dermatol 2005; 23:171–181.

    Article  PubMed  Google Scholar 

  2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272–1285.

    Article  PubMed  CAS  Google Scholar 

  3. Vaillant L. [Mechanisms of cutaneous drug reactions]. Rev Prat 2000; 50:1294–1299.

    PubMed  CAS  Google Scholar 

  4. Barbaud A. Toxidermies immunoallergiques chez ’immunocompétent. Encycl Méd Chir, Dermatologie, 2004; 98-478-A-10:1–7.

    Google Scholar 

  5. Chosidow O. [Drug-induced exanthemas]. Rev Prat 2000; 50:1310–1313.

    PubMed  CAS  Google Scholar 

  6. Djien V, Bocquet H, Dupuy A et al. Symptomatologie et marqueurs de sévérité des toxidermies érythémateuses. Ann Dermatol Venereol 1999; 126:247–250.

    PubMed  CAS  Google Scholar 

  7. Martin S, Barbaud A, Schmutz JL et al. Polyclonalité de la réponse lymphocytaire T dans les tests d’activation lymphocytaire médicamenteux. Ann Dermatol Venereol 2000; 127:268–272.

    PubMed  CAS  Google Scholar 

  8. Mauri-Helweg D, Zanni M, Frei E et al. Cross-reactivity of T cell clones to beta-lactam antibiotics. J Immunol 1996; 157:1071–1079.

    Google Scholar 

  9. Barbaud A, Reichert-Penetrat S, Trechot P et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139:49–58.

    Article  PubMed  CAS  Google Scholar 

  10. Barbaud A, Bene MC, Faure G, Schmutz JL. Tests cutanés dans ’exploration des toxidermies supposées de mécanisme immunoallergique. Bull Acad Natl Med 2000; 184:47–63.

    Google Scholar 

  11. Grosshans E. [Drug-induced urticaria]. Rev Prat 2000; 50:1305–1309.

    PubMed  CAS  Google Scholar 

  12. Silverman E, In KH, Yandava C, Drazen M. Pharmacogenetics of the 5-lipoxygenase pathway in asthma. Clin Exp Allergy 1998; 28:164s–170s.

    Article  Google Scholar 

  13. Viola M, Quaratino D, Gaeta F et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to monsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 137:145–150.

    Article  PubMed  CAS  Google Scholar 

  14. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers inpatients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000; 34:526–528.

    Article  PubMed  CAS  Google Scholar 

  15. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 2004; 126:400–404.

    Article  PubMed  CAS  Google Scholar 

  16. Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Fenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158: 2063–2065.

    Article  PubMed  Google Scholar 

  17. Fays S, Trechot P, Schmutz JL et al. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol 2003; 148:171–172.

    Article  Google Scholar 

  18. Chandeclerc ML, Martin S, Petitpain N et al. Tadalafil and palpebral edema. South Med J 2004; 97:1142–1143.

    Article  PubMed  Google Scholar 

  19. Cousin F, Catelain A, Philips K et al. Ľhypersensibilité immédiate est rarement en cause dans les urticaires médicamenteuses. Ann Dermatol Venereol 2003; 130:321–324.

    PubMed  CAS  Google Scholar 

  20. Beylot C, Bioulac P, Doutre MS. Pustulose exanthématique aiguë généralisée (quatre cas). Ann Dermatol Venereol 1980; 107:37–48.

    PubMed  CAS  Google Scholar 

  21. Machet L, Martin L, Vaillant L. Pustulose exanthématique aiguë généralisée. Ann Dermatol Venereol 2001; 128:73–79.

    PubMed  CAS  Google Scholar 

  22. Sidoroff A, Halevy S, Bavinck JN et al. Acute generalized exanthematous pustulosis (AGEP). A clinical reaction pattern. J Cutan Pathol 2001; 28:113–119.

    Article  PubMed  CAS  Google Scholar 

  23. Roujeau J-C, Bioulac Sage P, Bourseau C et al. Acute generalized exanthematous pustulosis. Arch Dermatol 1991; 127:1333–1338.

    Article  PubMed  CAS  Google Scholar 

  24. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001: 107: 1433–1441.

    Article  PubMed  CAS  Google Scholar 

  25. Wolkenstein P, Chosidow P, Flechet M-L et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35:234–236.

    Article  PubMed  CAS  Google Scholar 

  26. Saissi E-H, Beau-Salinas F, Jonville-Béra A-P et al. Médicaments associés à la survenue d’une pustulose exanthématique aigué généralisée. Ann Dermatol Venereol 2003; 130:612–618.

    PubMed  Google Scholar 

  27. Lee AY. Fixed drug eruptions. Am J Clin Dermatol 2000; 1:277–285.

    Article  PubMed  CAS  Google Scholar 

  28. Korkij W, Soltani K. Fixed drug eruption. Arch Dermatol 1984; 120: 520–524.

    Article  PubMed  CAS  Google Scholar 

  29. Alanko K. Topical provocation of fixed drug eruption: a study of 30 patients. Contact Dermatitis 1994; 31:25–27.

    Article  PubMed  CAS  Google Scholar 

  30. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS. Semin Cutan Med Surg 1996; 15:250–257.

    Article  PubMed  CAS  Google Scholar 

  31. Begon E, Roujeau JC. Syndrome d’hypersensibilité médicamenteuse ou DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Ann Dermatol Venereol 2004; 131:293–297.

    PubMed  CAS  Google Scholar 

  32. Bonnetblanc JM. Drug hypersensitivity syndrome. Dermatology 1993; 187:84–85.

    Article  PubMed  CAS  Google Scholar 

  33. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209: 209–216.

    Article  PubMed  CAS  Google Scholar 

  34. Descamps V, Valance A, Eldinger C et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137:301–304.

    PubMed  CAS  Google Scholar 

  35. Hashimoto K, Yasukawa M, Tohyama M. Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 2003; 3:255–260.

    Article  PubMed  CAS  Google Scholar 

  36. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140:183–188.

    Article  PubMed  Google Scholar 

  37. Wong GAE, Shear N. Is a drug alone sufficient to cause the drug hypersensitivity syndrome? Arch Dermatol 2004; 140:226–230.

    Article  PubMed  Google Scholar 

  38. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92–96.

    Article  PubMed  CAS  Google Scholar 

  39. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019–1024.

    Article  PubMed  Google Scholar 

  40. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131:539–543.

    Article  PubMed  CAS  Google Scholar 

  41. Côté B, Wechsler J, Bastuji-Garin S et al. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995; 131:1268–1272.

    Article  PubMed  Google Scholar 

  42. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102:s28–s30.

    Article  Google Scholar 

  43. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600–1607.

    Article  PubMed  CAS  Google Scholar 

  44. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272–1285.

    Article  PubMed  CAS  Google Scholar 

  45. Ghislain P-D, Roujeau J-C. Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity syndrome. Dermatol Online J 2002; 8:5.

    PubMed  Google Scholar 

  46. Ito K, Hara H, Okada T et al. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-Ligand expression. Clin Exp Dermatol 2004; 29:679–680.

    Article  PubMed  CAS  Google Scholar 

  47. Wetterwald E, Chosidow O, Bachot N, Roujeau JC. Syndrome de Lyell (nécrolyse épidermique toxique). Encycl Méd Chir, Dermatologie, 98-270-A10, 2001, 13 p.

    Google Scholar 

  48. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1997; 133:845–849.

    Article  PubMed  CAS  Google Scholar 

  49. Paul C, Wolkenstein P, Adle H et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134:710–714.

    PubMed  CAS  Google Scholar 

  50. Barbaud A. Démarche diagnostique devant une toxidermie. Concours médical 2003; 125: 1259–1266.

    Google Scholar 

  51. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidlines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321–328.

    Article  PubMed  CAS  Google Scholar 

  52. Barbaud A, Trechot P, Reichert-Penetrat S et al. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:265–268.

    Article  PubMed  CAS  Google Scholar 

  53. Kleinhans M, Linzbach L, Zedlitz S et al. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 2002; 47:100–102.

    Article  PubMed  Google Scholar 

  54. Demoly P. Anaphylactic reactions—value of skin and provocation tests. Toxicology 2005; 209:221–223

    Article  PubMed  CAS  Google Scholar 

  55. Ponvert C, Le Clainche L, de Blic J et al. Allergy to beta-lactam antibiotics in children. Pediatrics 1999; 104:e45.

    Article  PubMed  CAS  Google Scholar 

  56. Romano A, Gueant-Rodriguez RM et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141: 16–22.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Annick Barbaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Barbaud, A. (2007). Toxidermies avec manifestations systémiques. In: Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées. Springer, Paris. https://doi.org/10.1007/978-2-287-33886-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-33886-1_18

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-33885-4

  • Online ISBN: 978-2-287-33886-1

Publish with us

Policies and ethics

Search

Navigation